Cargando…

An Immunogenic Cell Death-Related Classification Predicts Prognosis and Response to Immunotherapy in Head and Neck Squamous Cell Carcinoma

Immunogenic cell death (ICD) has been classified as a form of regulated cell death (RCD) that is sufficient to activate an adaptive immune response. Accumulating evidence has demonstrated the ability of ICD to reshape the tumor immune microenvironment through the emission of danger signals or DAMPs,...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xinwen, Wu, Shouwu, Liu, Feng, Ke, Dianshan, Wang, Xinwu, Pan, Dinglong, Xu, Weifeng, Zhou, Ling, He, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640500/
https://www.ncbi.nlm.nih.gov/pubmed/34868055
http://dx.doi.org/10.3389/fimmu.2021.781466
_version_ 1784609344291078144
author Wang, Xinwen
Wu, Shouwu
Liu, Feng
Ke, Dianshan
Wang, Xinwu
Pan, Dinglong
Xu, Weifeng
Zhou, Ling
He, Weidong
author_facet Wang, Xinwen
Wu, Shouwu
Liu, Feng
Ke, Dianshan
Wang, Xinwu
Pan, Dinglong
Xu, Weifeng
Zhou, Ling
He, Weidong
author_sort Wang, Xinwen
collection PubMed
description Immunogenic cell death (ICD) has been classified as a form of regulated cell death (RCD) that is sufficient to activate an adaptive immune response. Accumulating evidence has demonstrated the ability of ICD to reshape the tumor immune microenvironment through the emission of danger signals or DAMPs, which may contribute to the immunotherapy. Currently, identification of ICD-associated biomarkers that stratify patients according to their benefit from ICD immunotherapy would be of great advantage. Here, we identified two ICD-associated subtypes by consensus clustering. ICD-high subtype was associated with the favorable clinical outcomes, abundant immune cell infiltration, and high activity of immune response signaling. Besides, we established and validated an ICD-related prognostic model that predicted the survival of HNSCC and was associated with tumor immune microenvironment. In conclusion, we established a new classification system of HNSCC based on ICD signatures. This stratification had significant clinical outcomes for estimating prognosis, as well as the immunotherapy of HNSCC patients
format Online
Article
Text
id pubmed-8640500
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86405002021-12-04 An Immunogenic Cell Death-Related Classification Predicts Prognosis and Response to Immunotherapy in Head and Neck Squamous Cell Carcinoma Wang, Xinwen Wu, Shouwu Liu, Feng Ke, Dianshan Wang, Xinwu Pan, Dinglong Xu, Weifeng Zhou, Ling He, Weidong Front Immunol Immunology Immunogenic cell death (ICD) has been classified as a form of regulated cell death (RCD) that is sufficient to activate an adaptive immune response. Accumulating evidence has demonstrated the ability of ICD to reshape the tumor immune microenvironment through the emission of danger signals or DAMPs, which may contribute to the immunotherapy. Currently, identification of ICD-associated biomarkers that stratify patients according to their benefit from ICD immunotherapy would be of great advantage. Here, we identified two ICD-associated subtypes by consensus clustering. ICD-high subtype was associated with the favorable clinical outcomes, abundant immune cell infiltration, and high activity of immune response signaling. Besides, we established and validated an ICD-related prognostic model that predicted the survival of HNSCC and was associated with tumor immune microenvironment. In conclusion, we established a new classification system of HNSCC based on ICD signatures. This stratification had significant clinical outcomes for estimating prognosis, as well as the immunotherapy of HNSCC patients Frontiers Media S.A. 2021-11-19 /pmc/articles/PMC8640500/ /pubmed/34868055 http://dx.doi.org/10.3389/fimmu.2021.781466 Text en Copyright © 2021 Wang, Wu, Liu, Ke, Wang, Pan, Xu, Zhou and He https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Wang, Xinwen
Wu, Shouwu
Liu, Feng
Ke, Dianshan
Wang, Xinwu
Pan, Dinglong
Xu, Weifeng
Zhou, Ling
He, Weidong
An Immunogenic Cell Death-Related Classification Predicts Prognosis and Response to Immunotherapy in Head and Neck Squamous Cell Carcinoma
title An Immunogenic Cell Death-Related Classification Predicts Prognosis and Response to Immunotherapy in Head and Neck Squamous Cell Carcinoma
title_full An Immunogenic Cell Death-Related Classification Predicts Prognosis and Response to Immunotherapy in Head and Neck Squamous Cell Carcinoma
title_fullStr An Immunogenic Cell Death-Related Classification Predicts Prognosis and Response to Immunotherapy in Head and Neck Squamous Cell Carcinoma
title_full_unstemmed An Immunogenic Cell Death-Related Classification Predicts Prognosis and Response to Immunotherapy in Head and Neck Squamous Cell Carcinoma
title_short An Immunogenic Cell Death-Related Classification Predicts Prognosis and Response to Immunotherapy in Head and Neck Squamous Cell Carcinoma
title_sort immunogenic cell death-related classification predicts prognosis and response to immunotherapy in head and neck squamous cell carcinoma
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640500/
https://www.ncbi.nlm.nih.gov/pubmed/34868055
http://dx.doi.org/10.3389/fimmu.2021.781466
work_keys_str_mv AT wangxinwen animmunogeniccelldeathrelatedclassificationpredictsprognosisandresponsetoimmunotherapyinheadandnecksquamouscellcarcinoma
AT wushouwu animmunogeniccelldeathrelatedclassificationpredictsprognosisandresponsetoimmunotherapyinheadandnecksquamouscellcarcinoma
AT liufeng animmunogeniccelldeathrelatedclassificationpredictsprognosisandresponsetoimmunotherapyinheadandnecksquamouscellcarcinoma
AT kedianshan animmunogeniccelldeathrelatedclassificationpredictsprognosisandresponsetoimmunotherapyinheadandnecksquamouscellcarcinoma
AT wangxinwu animmunogeniccelldeathrelatedclassificationpredictsprognosisandresponsetoimmunotherapyinheadandnecksquamouscellcarcinoma
AT pandinglong animmunogeniccelldeathrelatedclassificationpredictsprognosisandresponsetoimmunotherapyinheadandnecksquamouscellcarcinoma
AT xuweifeng animmunogeniccelldeathrelatedclassificationpredictsprognosisandresponsetoimmunotherapyinheadandnecksquamouscellcarcinoma
AT zhouling animmunogeniccelldeathrelatedclassificationpredictsprognosisandresponsetoimmunotherapyinheadandnecksquamouscellcarcinoma
AT heweidong animmunogeniccelldeathrelatedclassificationpredictsprognosisandresponsetoimmunotherapyinheadandnecksquamouscellcarcinoma
AT wangxinwen immunogeniccelldeathrelatedclassificationpredictsprognosisandresponsetoimmunotherapyinheadandnecksquamouscellcarcinoma
AT wushouwu immunogeniccelldeathrelatedclassificationpredictsprognosisandresponsetoimmunotherapyinheadandnecksquamouscellcarcinoma
AT liufeng immunogeniccelldeathrelatedclassificationpredictsprognosisandresponsetoimmunotherapyinheadandnecksquamouscellcarcinoma
AT kedianshan immunogeniccelldeathrelatedclassificationpredictsprognosisandresponsetoimmunotherapyinheadandnecksquamouscellcarcinoma
AT wangxinwu immunogeniccelldeathrelatedclassificationpredictsprognosisandresponsetoimmunotherapyinheadandnecksquamouscellcarcinoma
AT pandinglong immunogeniccelldeathrelatedclassificationpredictsprognosisandresponsetoimmunotherapyinheadandnecksquamouscellcarcinoma
AT xuweifeng immunogeniccelldeathrelatedclassificationpredictsprognosisandresponsetoimmunotherapyinheadandnecksquamouscellcarcinoma
AT zhouling immunogeniccelldeathrelatedclassificationpredictsprognosisandresponsetoimmunotherapyinheadandnecksquamouscellcarcinoma
AT heweidong immunogeniccelldeathrelatedclassificationpredictsprognosisandresponsetoimmunotherapyinheadandnecksquamouscellcarcinoma